Eliem Therapeutics (ELYM) Stock Chart & Stock Price History $1.61 -0.04 (-2.42%) As of 08/12/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Eliem Therapeutics Stock Price Performance The Eliem Therapeutics (ELYM) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 73.21%, with a year-to-date return of -12.97%. In the past month, the stock has increased 17.52%, reflecting recent market activity. As of the latest close, Eliem Therapeutics traded at $1.61 with a market cap of $47.90 million and volume of 492,154 shares. Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-5.29%1 Month Performance+17.52%3 Month Performance+26.77%Year-To-Date Performance-12.97%1 Year Performance-73.21% ELYM Stock Chart for Thursday, August, 14, 2025 ELYM Chart by TradingView Eliem Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/13/2025$1.65$1.61-2.42%$1.68$1.55492,154 shs$47.90 million08/12/2025$1.70$1.65-2.94%$1.72$1.64370,703 shs$49.09 million08/11/2025$1.70$1.70$1.75$1.66260,942 shs$50.58 million08/08/2025$1.70$1.70$1.78$1.664.70 million shs$50.58 million08/07/2025$1.70$1.70$1.78$1.664.70 million shs$50.58 million08/06/2025$1.70$1.70$1.78$1.664.70 million shs$50.58 million08/05/2025$1.45$1.70+17.24%$1.78$1.664.70 million shs$50.58 million08/04/2025$1.45$1.45$1.46$1.36145,775 shs$43.14 million08/01/2025$1.51$1.51$1.64$1.50249,534 shs$44.93 million07/31/2025$1.51$1.51$1.64$1.50249,534 shs$44.93 million Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/30/2025$1.60$1.51-5.63%$1.64$1.50249,534 shs$44.93 million07/29/2025$1.45$1.60+10.34%$1.65$1.46773,699 shs$47.60 million07/28/2025$1.45$1.45$1.51$1.43116,267 shs$43.14 million07/25/2025$1.48$1.48$1.53$1.4097,970 shs$44.03 million07/24/2025$1.41$1.48+4.96%$1.48$1.3859,580 shs$44.03 million07/23/2025$1.51$1.41-6.62%$1.44$1.3764,961 shs$41.95 million07/22/2025$1.51$1.51$1.55$1.45159,187 shs$44.93 million07/21/2025$1.51$1.51$1.55$1.45159,187 shs$44.93 million07/18/2025$1.40$1.46+4.29%$1.51$1.40238,236 shs$43.44 million07/17/2025$1.37$1.40+2.19%$1.43$1.37190,980 shs$41.65 million07/16/2025$1.42$1.37-3.52%$1.42$1.3582,472 shs$40.76 million07/15/2025$1.37$1.42+3.65%$1.45$1.35165,418 shs$42.25 million07/14/2025$1.37$1.37$1.39$1.32246,292 shs$40.76 million Related Companies Instil Bio Stock Price Chart Rapt Therapeutics Stock Price Chart Cardiff Oncology Stock Price Chart Lifevantage Stock Price Chart Aclaris Therapeutics Stock Price Chart Journey Medical Stock Price Chart Puma Biotechnology Stock Price Chart BioAge Labs Stock Price Chart Acurx Pharmaceuticals Stock Price Chart SELLAS Life Sciences Group Stock Price Chart Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ELYM) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access